Phase III Medical

Lisata Therapeutics (Nasdaq: LSTA) is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for advanced solid tumors and other serious diseases. The company's corporate history is marked by several significant transitions, having previously operated under the names Phase III Medical Co., NeoStem, Inc., and Caladrius Biosciences, Inc. Lisata's current lead product candidate is LSTA1 (formerly CEND-1), an investigational cyclic peptide that activates a novel uptake pathway to enhance the delivery of co-administered anti-cancer drugs into solid tumors. The company is currently conducting multiple Phase 2 clinical trials evaluating LSTA1 in combination with standard-of-care regimens for indications such as pancreatic cancer, glioblastoma, and other solid tumors. Lisata was formed through the 2022 merger of Caladrius Biosciences and Cend Therapeutics, consolidating a pipeline focused on tumor-targeting technologies.